ALLSCHWIL/BASEL, SWITZERLAND - 17 March 2014 - Actelion Ltd (ATLN.VX) today announced the results of COMPASS-2, a Phase IV, prospective, randomized, double-blind, placebo-controlled, event-driven ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed ® announced today that the first patients have been enrolled in the COMPaSS™ study. COMPaSS, Clinical Outcome Measures in Personalized aprevo ® Spine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results